ASCO Backs Routine ESR1 Testing for Certain Breast Cancers

Activity of elacestrant in EMERALD trial 'provides strong signal' for guideline update

Related Keywords

United States ,Dana Farber Cancer Institute ,Massachusetts ,Boston ,American ,Mike Bassett ,Harold Burstein ,Expert Panel ,American Society Of Clinical Oncology ,Clinical Laboratory Improvement Amendments ,American Society ,Clinical Oncology ,Rapid Recommendation ,Clin Oncol ,